Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
- Stepping Up Enforcement Efforts On Stem Cell Therapies on December 18, 2018 at 11:47 pm
The only stem cell based products that are FDA approved for use within ... Around the world doctors now routinely use stems cells from bone marrow or blood transplant procedures to treat cancer and di... […]
- Global Transplant Complications Drug Development Pipeline Review 2018 Featuring Medeor Therapeutics, Amgen and Novartis on December 18, 2018 at 4:21 pm
GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include ... […]
- Bone marrow transplant survival rates recognized nationally on December 18, 2018 at 9:35 am
The results were issued in an annual report by the Center for International Blood and Marrow Transplant Research®, designed to provide potential stem cell transplant recipients, their families and the ... […]
- Is Bloodless Transplant Feasible in Multiple Myeloma? on December 14, 2018 at 3:35 pm
Undergoing bloodless autologous stem cell transplantation (BL-ASCT) was a viable option for patients with multiple myeloma who were unwilling to receive blood products, according to a single-center re... […]
- CAR T-Cell Program Feasibility in the Community Setting on December 14, 2018 at 11:57 am
There are many challenges again to outpatient delivery of CAR T-cell therapy. Here in Seattle we have extensive experience in being able to do that, but that’s because we have a very robust transplant ... […]
- Regenerative Medicine Foundation Announces 2019 “Stem Cell and Regenerative Medicine Action Award” Honorees on December 14, 2018 at 9:14 am
bone marrow-/cord blood-derived hematopoietic stem cell transplantation and cellular immunotherapy (such as CAR-T, NK, DC, CIK). Founded by Professor Daopei Lu, the hospital group is ... […]
- Allogeneic stem cell transplant induces long-term responses in follicular lymphoma on December 13, 2018 at 2:05 pm
Nonmyeloablative allogeneic stem cell transplant results in complete responses that last for up to a decade among patients with relapsed follicular lymphoma, including individuals who receive transpla... […]
- Newly Published Case Series Demonstrates the Karius Test's Effectiveness for Monitoring Infections in Stem-Cell Transplant Pa... on December 13, 2018 at 4:07 am
REDWOOD CITY, Calif., Dec. 13, 2018 /PRNewswire-PRWeb/ -- Karius, Inc., a life sciences company transforming infectious disease diagnostics with genomics, announced today the results of an ongoing cli... […]
- Multiple sclerosis stem cell breakthrough gives patients new hope on December 11, 2018 at 11:18 am
After trying a number of common MS medications for nearly four yearswith no success, she became so desperateshe looked into travelling to Russia for a risky, unproven stem cell transplant. "I booked t... […]
- Nitro church holding blood drive in honor of bone marrow transplant recipient on December 11, 2018 at 5:51 am
“After receiving aggressive treatment, including a stem cell transplant, Logan is in remission. His family hopes his story will inspire others to give blood in honor of Logan to help other patients in ... […]
via Google News and Bing News